Moderna (MRNA)
(Delayed Data from NSDQ)
$118.75 USD
-2.43 (-2.01%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $118.84 +0.09 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.75 USD
-2.43 (-2.01%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $118.84 +0.09 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
MRNA vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MRNA vs. TECH: Which Stock Is the Better Value Option?
Company News for Aug 4, 2022
by Zacks Equity Research
Companies in The News Are: MRNA, REGN, HZNP, EXC
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
by Zacks Equity Research
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.
U.S. Stock Futures Rise on Strong Q2 Earnings
by Zacks Equity Research
Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.
Pre-markets Green on Strong Earnings Numbers
by Zacks Equity Research
Pre-markets Green on Strong Earnings Numbers.
Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Moderna (MRNA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $165.69, marking a +1.33% move from the previous day.
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $166.89, moving -0.15% from the previous trading session.
Novavax (NVAX) Up as CDC Endorses COVID Jab for Use in Adults
by Zacks Equity Research
Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.
Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.
Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada
by Zacks Equity Research
Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.
Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label
by Zacks Equity Research
The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.
Novavax's (NVAX) Protein-Based COVID Jab Gets EUA in the US
by Zacks Equity Research
Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
by Zacks Equity Research
Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
Novavax (NVAX) Inks COVID Jab Supply Deal With US Government
by Zacks Equity Research
Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.
Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.
Moderna (MRNA) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $175.26, moving -0.55% from the previous trading session.
PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.
Stock Market News for Jul 11, 2022
by Zacks Equity Research
Wall Street had a mixed day on Friday in a choppy session of trading.
Company News for Jul 8, 2022
by Zacks Equity Research
Companies In The News Are: GME, MRNA, LCID, SLP.
Novavax (NVAX) Stock Rallies 26.8% in a Month: Here's Why
by Zacks Equity Research
FDA's advisory committee supports granting authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. The vaccine also receives authorization for use in adolescents in Europe.